Skip to main content
Clinical Trials/NCT01771627
NCT01771627
Completed
Not Applicable

Pilot Study of Varenicline vs. Nicotine Patch Delivered by a Telephone Quitline to Promote Smoking Cessation

Roswell Park Cancer Institute1 site in 1 country300 target enrollmentOctober 22, 2012

Overview

Phase
Not Applicable
Intervention
varenicline
Conditions
Tobacco Use Disorder
Sponsor
Roswell Park Cancer Institute
Enrollment
300
Locations
1
Primary Endpoint
Quit Rate
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This pilot clinical trial studies varenicline or nicotine patch in promoting smoking cessation among current smokers. Varenicline or nicotine patch may help people stop smoking

Detailed Description

PRIMARY OBJECTIVES: I. To determine if mail delivery of 12 weeks of varenicline results in improved smoking cessation outcomes relative to nicotine replacement therapy (NRT) in 300 smokers. II. To determine if delivery of varenicline is cost-effective as compared to nicotine patch. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients undergo general smoking cessation counseling and receive varenicline orally (PO) twice daily (QD) on days 1-28. Courses repeat every 28 days for up to 12 weeks. ARM II: Patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks. After completion of study treatment, patients are followed up at 4 months.

Registry
clinicaltrials.gov
Start Date
October 22, 2012
End Date
August 28, 2015
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Cigarette smokers who call the New York State Smokers' Quitline requesting assistance with quitting smoking
  • State that they are under the care of a primary care physician
  • Are eligible for receipt of pharmacotherapy by mail using the standard NRT criteria
  • Speak English
  • Answer "no" to the following 3 questions:
  • "Have you ever been diagnosed with or treated for a mental health problem like major depression, bipolar disorder, dysthymia, or schizoaffective disorder?"
  • "Have you ever had serious thoughts of killing or hurting yourself, ever have any intention or plan to carry out these thoughts, or actually attempted to kill yourself?"
  • "Is there any reason that you cannot use varenicline/Chantix?"

Exclusion Criteria

  • State that they are not under the care of a primary care physician
  • Are not eligible for receipt of pharmacotherapy by mail using the standard NRT criteria
  • Do not speak English
  • Answer "yes" to the question, "have you ever been diagnosed with or treated for a mental health problem like major depression, bipolar disorder, dysthymia, or schizoaffective disorder?"
  • Answer "yes" to the question, "have you ever had serious thoughts of killing or hurting yourself, ever have any intention or plan to carry out these thoughts, or actually attempted to kill yourself?"
  • Answer "yes" to the question, "is there any reason that you cannot use varenicline/Chantix?"
  • Are women who are currently pregnant
  • Report that they are unwilling to receive or take varenicline on screening

Arms & Interventions

Arm I (varenicline)

Patients undergo general smoking cessation counseling and receive varenicline PO QD on days 1-28. Courses repeat every 28 days for up to 12 weeks.

Intervention: varenicline

Arm II (nicotine patch)

Patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks.

Intervention: nicotine patch

Outcomes

Primary Outcomes

Quit Rate

Time Frame: 4 months

The quit rate at 4 months will be compared between the 2 groups, using a logistic regression analysis with a 2-side 95% confidence interval.

Study Sites (1)

Loading locations...

Similar Trials